Trial · NCT04790279

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

NCT04790279, Phase 4, Completed, Prisma Health-Upstate; results first posted 2024-10-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension. Trials, record NCT04790279. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04790279

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension
NCT number: NCT04790279
Status: Completed
Phases: Phase 4
Enrollment: 175 participants, actual
Lead sponsor: Prisma Health-Upstate
Conditions: Hypertension in Pregnancy
Interventions: Amlodipine, NIFEdipine ER
First posted: 2021-03-10
Last updated: 2024-10-28
Results first posted: 2024-10-28

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Length of Stay	Through hospital stay, on average 2-5 days	length of stay from delivery until discharge
Secondary	Number of Acute Treatments After Medication Initiation	Through hospital stay, on average 2-5 days
Secondary	Patient Reported Side Effects	Through hospital stay, on average 2-5 days	Side effects based on patient reported survey where 1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = always
Secondary	Number of Patients Discontinuing Medication Due to Side Effects	Through hospital stay, on average 2-5 days
Secondary	Number of Patients Requiring Hospital Readmission	until 6 weeks postpartum
Secondary	Breastfeeding Duration of 6+ Weeks	until 6 weeks postpartum
Secondary	Number of Patients Reporting Satisfaction With Breastfeeding Experience on Patient-completed Questionnaire	until 6 weeks postpartum

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Length of Stay	Through hospital stay, on average 2-5 days	Amlodipine Intent To Treat	hours	MEDIAN
SECONDARY	Number of Acute Treatments After Medication Initiation	Through hospital stay, on average 2-5 days	Patients who received at least 1 dose of assigned study medication at correct starting dose	number acute treatments	MEDIAN
SECONDARY	Patient Reported Side Effects	Through hospital stay, on average 2-5 days	Patients receiving at least 1 dose of assigned study medication at correct starting dose	score on a scale	MEDIAN
SECONDARY	Number of Patients Discontinuing Medication Due to Side Effects	Through hospital stay, on average 2-5 days		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Patients Requiring Hospital Readmission	until 6 weeks postpartum		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Breastfeeding Duration of 6+ Weeks	until 6 weeks postpartum	Only includes patients who answered relevant question on breastfeeding questionnaire	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Patients Reporting Satisfaction With Breastfeeding Experience on Patient-completed Questionnaire	until 6 weeks postpartum	Only includes patients who answered relevant question on breastfeeding questionnaire	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Length of Stay	Amlodipine		73.5	95% Confidence Interval 67.0 to 81.0	hours
Length of Stay	Nifedipine ER		72.0	95% Confidence Interval 66.5 to 78.5	hours
Number of Acute Treatments After Medication Initiation	Amlodipine		4.0	Standard Deviation 2.7	number acute treatments
Number of Acute Treatments After Medication Initiation	Nifedipine ER		1.5	Standard Deviation 1.5	number acute treatments
Patient Reported Side Effects	Amlodipine	Flushing	1.33	Standard Deviation 0.72	score on a scale
Patient Reported Side Effects	Nifedipine ER	Flushing	1.60	Standard Deviation 1.00	score on a scale
Patient Reported Side Effects	Amlodipine	Swelling	1.55	Standard Deviation 1.16	score on a scale
Patient Reported Side Effects	Nifedipine ER	Swelling	1.71	Standard Deviation 1.09	score on a scale
Patient Reported Side Effects	Amlodipine	Headaches	1.71	Standard Deviation 1.06	score on a scale
Patient Reported Side Effects	Nifedipine ER	Headaches	1.98	Standard Deviation 1.17	score on a scale

1 to 10 of 20Source ClinicalTrials.gov

See all 20 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Amlodipine	87
Overall Study	STARTED	Nifedipine ER	88
Overall Study	COMPLETED	Amlodipine	51
Overall Study	COMPLETED	Nifedipine ER	69
Overall Study	NOT COMPLETED	Amlodipine	36
Overall Study	NOT COMPLETED	Nifedipine ER	19

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Prolonged hospitalization	Pregnancy, puerperium and perinatal conditions	Amlodipine	14	53
other	Prolonged hospitalization	Pregnancy, puerperium and perinatal conditions	Nifedipine ER	11	69
other	Side effect requiring discontinuation	Pregnancy, puerperium and perinatal conditions	Amlodipine	0	53
other	Side effect requiring discontinuation	Pregnancy, puerperium and perinatal conditions	Nifedipine ER	7	69
other	Triage/ER visit	Pregnancy, puerperium and perinatal conditions	Amlodipine	5	53
other	Triage/ER visit	Pregnancy, puerperium and perinatal conditions	Nifedipine ER	9	69
serious	Readmission	Pregnancy, puerperium and perinatal conditions	Amlodipine	3	53	3
serious	Readmission	Pregnancy, puerperium and perinatal conditions	Nifedipine ER	3	69	3
serious	Prolonged hospitalization	Pregnancy, puerperium and perinatal conditions	Amlodipine	1	53	1
serious	Prolonged hospitalization	Pregnancy, puerperium and perinatal conditions	Nifedipine ER	1	69	1

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Amlodipine	0	53
Total, all-cause mortality	Nifedipine ER	0	69
Total, other adverse events	Amlodipine	19	53
Total, other adverse events	Nifedipine ER	26	69
Total, serious adverse events	Amlodipine	4	53
Total, serious adverse events	Nifedipine ER	4	69

Source ClinicalTrials.gov

Papers9

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
1534716	BACKGROUND	PubMed
23633317	BACKGROUND	PubMed
24150027	BACKGROUND	PubMed
25447596	BACKGROUND	PubMed
27786578	BACKGROUND	PubMed
29187414	BACKGROUND	PubMed
30575675	BACKGROUND	PubMed
30575676	BACKGROUND	PubMed
31489020	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons6

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Amlodipine vs Nifedipine ER: Number of Patients Discontinuing Medication Due to Side Effects	Trial comparisons
Amlodipine vs Nifedipine ER: Number of Patients Requiring Hospital Readmission	Trial comparisons
Amlodipine vs Nifedipine ER: Number of Patients Reporting Satisfaction With Breastfeeding Experience on Patient-completed Questionnaire	Trial comparisons
Amlodipine vs Nifedipine ER: Breastfeeding Duration of 6+ Weeks	Trial comparisons
Amlodipine vs Nifedipine ER: deaths from any cause	Trial comparisons
Amlodipine vs Nifedipine ER: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04790279

GET https://conductscience.org/api/trials/v1/NCT04790279/registered

API reference For AI assistants